
Circe Biomedical, Inc. develops bioartificial liver assist devices for acute, end-stage liver failure treatment in the US.
Founded with a mission to revolutionize liver failure treatment, Circe Biomedical, Inc. focuses on developing advanced medical devices. Their flagship product is a bioartificial liver assist device designed to support patients suffering from acute, end-stage liver failure. By leveraging cutting-edge biomedical technology, Circe Biomedical aims to provide innovative solutions that enhance patient outcomes and address critical needs within the United States healthcare industry.
Circe Biomedical has garnered attention from notable figures in the medical and investment communities, contributing to its growing reputation. The company has achieved significant milestones in the development and clinical testing of its bioartificial liver assist device, positioning itself as a leader in the field of liver support systems. Through its pioneering work, Circe Biomedical is making a substantial impact on the treatment landscape for liver failure, offering new hope to patients and healthcare providers alike.

Circle Biologics

BiomedInnovations

Niche Biomedical

Biomimedica
biomimedica.com

Cirtec Medical
cirtecmed.com

Voyager Biomedical

Bigfoot Biomedical

Blaire Biomedical

Symic Biomedical

Halcyon Biomedical

International Biomedical Devices
aperturectc.com

SeaStar Medical

Early Bird Medical
earlybirdmed.com

enVVeno Medical
envveno.com

Beta Bionics
Companies similar to Circe Biomedical include Circle Biologics, BiomedInnovations, Niche Biomedical and Biomimedica.
Circe Biomedical was founded in 1999.
Circe Biomedical's headquarters is located in Lexington, MA, US.
Circe Biomedical's most recent funding round was for $28M (USD) in December 2000.
As of Dec 18, 2000, Circe Biomedical has raised a total of $28M (USD).
Circe Biomedical has 30 employees as of Feb 5, 2024.